Biotech Values

[DewDiligence]

Lucentis PIER results:

>>
At month 12, patients treated with Lucentis lost 1.6 letters and 0.2 letters (0.3 mg and 0.5 mg) compared to a loss of 16.3 letters in the sham group, on average [p<0.0001].
<<

I’m not convinced that this is good enough to make quarterly dosing of Lucentis the standard of care. Despite the obvious benefit in convenience and safety from quarterly vs monthly dosing, the efficacy at one year is clearly not as good with quarterly dosing as with monthly dosing.

I think DNA has more work to do to convince ophthalmologists that quarterly dosing is the way to go.